Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price hit a new 52-week high on Monday . The company traded as high as C$7.32 and last traded at C$7.32, with a volume of 3480 shares. The stock had previously closed at C$7.08.
Knight Therapeutics Stock Performance
The firm has a market cap of C$717.62 million, a P/E ratio of -146.40, a PEG ratio of -1,013.50 and a beta of 0.15. The company has a debt-to-equity ratio of 10.15, a current ratio of 2.39 and a quick ratio of 1.79. The stock's 50 day moving average is C$6.20 and its two-hundred day moving average is C$6.06.
Knight Therapeutics (TSE:GUD - Get Free Report) last announced its earnings results on Thursday, March 19th. The company reported C$0.09 EPS for the quarter. The business had revenue of C$133.20 million for the quarter. Knight Therapeutics had a negative return on equity of 0.70% and a negative net margin of 1.19%. As a group, equities analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
